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Abstract
Study objective To compare the live birth rate of women
presented with recurrent miscarriages in the ﬁrst trimester
due to antiphospholipid antibody syndrome (APS), ran-
domized to either low molecular weight heparin (Bemip-
arin) or low dose aspirin (LDA) and to determine the
maternal and fetal adverse effects in both treatment groups.
Patients and methods A clinical comparative study was
conductedinMaternityteachingHospital,Erbilcity,northof
Iraq, Kurdistan region from 15th of September 2007 to the
1st of August 2010 on 141 women presented with 2 or more
consecutive miscarriages due to APS, the women random-
ized to receive either prophylactic dose of Bemiparin with
the diagnosis of pregnancy or LDA started preconceptioally
and until 36 weeks gestation. The primary outcome was live
birth rate in both treatment groups, the secondary outcomes
were maternal and fetal complications in both trial groups.
Result There was no statistically signiﬁcant difference
between the two groups regarding demographic characters
(age groups, parity, gestational age and history of previous
abortion), and mode of delivery of the viable newborns.
There was a statistically signiﬁcant difference between the
two treatment groups regarding live birth rate. The pro-
portions of women who gave birth to a live infant were
72.13% in the LDA group and 86.25% in the Hibor group,
the mean difference between the live birth rate in both
group was 0.141 (95% Conﬁdence interval of the differ-
ence, 0.08, 0.274). The average birth weight for women
received LDA was signiﬁcantly lower than women who
received Bemiparin.
Conclusion The use of the new second generation
LMWH (Bemiparin) in comparison to LDA during preg-
nancy for prevention of recurrent miscarriage in women
with APS is a safe, reliable method with a high live birth
rate and no maternal and fetal complications.
Keywords Recurrent miscarriage  Low molecular
weight heparin  Bemiparin  Hibor  Low dose aspirin
Introduction
Recurrent miscarriage (RM) is traditionally deﬁned as
three or more consecutive miscarriages occurring before
20 weeks post-menstruation [1]. The American College of
Obstetrician and Gynecologists has recently stated that the
causes of recurrent fetal losses are similar in women who
have suffered two losses or more when compared with
women who have had three losses [2]. Approximately 1%
of all women trying to conceive have RMs; when RM is
deﬁned as two previous miscarriages, the proportion rises
to 5% [3]. They may or may not follow a successful birth.
About half of RMs are unexplained [4]. Medical investi-
gations usually begin after a third loss, but some centers
investigate after two losses on the basis that the risk of
failure in the next pregnancy increases substantially [5].
The European Society of Human Reproduction and
Embryology (ESHRE) Special Interest Group for Early
Pregnancy (SIGEP) protocol for the investigation and
medical management of RM, based on the data of recently
published large randomized controlled trials (RCTs) and
meta-analysis, recommended that basic investigations of a
couple presenting with RMs should include obstetric and
family history, age, BMI, and exposure to toxins, full blood
count, antiphospholipid antibodies (lupus anticoagulant
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ultrasound and/or hysterosalpingogram [6]. The most
compelling association between pregnancy loss and auto-
immune phenomena has been with the presence of anti-
phospholipid antibodies—Lupus anticoagulant and
anticardiolipin antibody [7]. Antiphospholipid antibody
syndrome is an autoimmune disease characterized by the
presence of antiphospholipid antibodies and at least one
clinical manifestation, the most common being venous or
arterial thrombosis and recurrent fetal loss. The syndrome
occurs in isolation, or in association with connective tissue
diseases, particularly systemic lupus erythematosus [8]. It
may coexist with several, predominantly autoimmune dis-
eases [9].
Pregnancy loss associated with antiphospholipid anti-
bodies (aPL) has traditionally been ascribed to thrombosis
of the utero-placental vasculature [10]; however, throm-
bosis is neither a universal nor a speciﬁc ﬁnding in aPL
pregnancies [11].
Management of APS focuses on anticoagulation; how-
ever, despite the solid evidence suggesting that this is the
best treatment option available, a lot of debates persist
regarding the intensity and duration of anticoagulation
needed in various subsets of APS. Thus there are currently
no uniformly agreement upon management algorithm for
APS [12]. Although several treatments have been advo-
cated, heparin and aspirin treatments are emerging as the
treatment of choice for APA syndrome associated with
recurrent pregnancy loss [13].
Dawes et al. [14] demonstrated that low molecular
weight heparin (LMWH) may be more effective than
unfractionated heparin, because it is more effectively
absorbed after subcutaneous administration and has a
longer half life in the circulation. This represents an
important role for LMWH in the treatment of APS in
pregnancy, because it causes less bleeding in both vaginal
and abdominal deliveries [15].
Many types of LMWH have been used alone or in
combination with aspirin low dose with different results in
different settings for prevention of miscarriages associated
with APS, but the current study is regarded as the ﬁrst one
using the new second generation LMWH (Bemiparin)
alone as a trial for prevention of RM due to APS.
Objectives
The primary outcome measure was to compare the live
birth rate in women presented with RM due to APS treated
with LMWH versus aspirin low dose, secondary outcomes
included obstetrical complications, fetal and maternal
adverse events in both treatment groups.
Patients and methods
A clinical comparative study was performed to investigate
whether treatment with LMWH versus ALD results in
increased live birth rate in women with history of RPL and
APS, in Maternity Teaching Hospital, Erbil city, Kurdistan
region, North of Iraq from 15th of September 2007 to the
1st of August 2010.
Participants
Inclusion criteria
Women considered participants in this trial fulﬁlled the
following criteria: aged 18–42 years at the time of inter-
view; a history of C2 unexplained consecutive pregnancy
losses before 20 weeks gestation; persistent presence of
anticardiolipin antibodies and or Lupus anticoagulant in
two occasions 8 weeks apart.
Exclusion criteria
The included Systemic Lupus Erythematosus, known
peptic ulcer disease, sensitivity to Aspirin or Heparin
depending on patients’ history report, previous venous
thromboembolic disease requiring ongoing anticoagulant
therapy and failure to consent to participate.
Cases with SLE were excluded from the study because
pregnant mothers with SLE should remain under medical
care until delivery, they have an extra increased risk for
pregnancy complications, usually they are on multiple
medications depending on the system involved by the
disease (patients require warfarn or cyclophosphamide
therapy should not get pregnant), they may be on Non-
steroidal antiinﬂammatory drugs, Anti-malarial drugs,
glucocorticoids, or immunosuppressive drugs like metho-
trexate. SLE may ﬂare up during pregnancy and has its own
complications regarding the fetus and newborn babies.
Other causes for RM were regarded as exclusion criteria.
Hormonal assay was carried out to exclude polycystic
ovarian syndrome and thyroid dysfunction, hyster-
osalpingogram/Ultrasound was done to exclude anatomical
causes for RM, cervical cultures for mycoplasma and urea
plasma to exclude bacterial vaginosis infection. To exclude
frank diabetes as a risk factor for RM, glucose tolerance
test was done for suspicious cases, karyotype analysis for
both parents was done for both parents depending on a
local laboratory in the city which was available recently in
our city, and other cases we depend on the results done
abroad by the patients themselves.
Only one case with type 1 diabetes mellitus was not
excluded from the study being a case with strictly
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123controlled blood sugar with a high level of anticardiolipin
antibody titer in two occasions.
Laboratory evaluation
To conﬁrm the diagnosis of APS in the participant, positive
serology was deﬁned as at least one of the following tests
to be positive in two occasions:
1. Anticardiolipin antibodies in medium to high titer
levels were identiﬁed using a standardized enzyme-
linked immunosorbent assay (ELISA) IgG [15 IgG
phospholipids units (GPL) or IgM[25 IgM phospho-
lipids units (MPL).
2. Lupus anticoagulant measured by prolonged phospho-
lipid-dependent coagulation (aPTT, Kaolin clotting
time, dilute Russell viper venom test, dilute PT), the
prolonged coagulation time was failed to be corrected
by a mix with platelet poor plasma and the prolonga-
tion of coagulation time was also corrected with excess
phospholipids [16].
3. Anti-b2 glycoprotein 1 IgG and/or IgM isotype in
serum or plasma is also regarded as one of the
criteria for diagnosis of APS, it was not done in the
current trial because the method was not available in
our city and to diagnose APS at least one of the
clinical criteria and only one of the laboratory criteria
should be met.
Sample size
The sample size consists of 146 ladies presented to the
maternity teaching hospital, with RM, clinical and labo-
ratory evaluation done for all the cases; all known causes
for RM were excluded except for APS and they were asked
to attained the hospital as soon as they miss a period of
their menstrual cycle. Both groups were advised to use
prenatal folic acid, the LDA group women were given the
drug assuming that the pregnancy occurs if she was not
using any contraception. The study time was about 3 years
and most of patients got pregnant within this period of time
except ﬁve cases who were referred to a special infertility
unit in the maternity teaching hospital. Sixty-one cases
were randomly assigned to receive Low Dose Aspirin
(LDA) before pregnancy was diagnosed at suspected
month and continued throughout pregnancy till 36 weeks
gestation, the other group of 80 cases were assigned to
receive LMWH (Bemiparin) with the diagnosis of preg-
nancy. Pregnancy in both groups was conﬁrmed by either
two rising quantitative beta human chorionic gonadotropin
(bhCG) hormone 48 h apart or by ultrasound conﬁrming
fetal heart activity, randomization to the treatment group
done using alternative criteria, the 1st case attained the
hospital complaining from RM and proved to have APS,
was randomized to LDA group, the second case attained
the hospital and full ﬁlled the inclusion criteria; LMWH
was prescribed to her, sometimes two cases of Heparin
followed one case of LDA. All the cases received the drug
randomly.
Clinical assessments
All women in the two treatment groups were evaluated
every 6 weeks during their pregnancy. The assessment
included detailed history, obstetrical and general exami-
nation, a specially designed questionnaire to record the
obstetrical data at each visit, fetal development and well-
being as well as maternal complications. Delivery infor-
mation was obtained from the obstetrician on call at the
time of labor for cases which delivered spontaneously
vaginally, and cases which delivered abdominally.
Side effects of both medications were asked for by each
woman and recorded in the same questionnaire.
The trial drugs
Bemiparin sodium (Hibor; Laboratories Rovi Pharmaceu-
ticals, a Spanish integrated and specialist company) is a
LMWH with a lower mean molecular weight (3,600 D)
and a higher anti—FXa/F11a ratio (8:1) than other
LMWHs. Bemiparin 2,500 IU anti Xa/0.2 ml solution for
injection in pre-ﬁlled syringes was provided for each
patient in the heparin group; all patients were taught to self
inject the medication subcutaneously once daily in the
anterior abdominal wall or anterior aspect of upper thigh
until 36 weeks of gestation.
ASPIRIN protect 100, BAYAR Company, (active
ingredient: Acetyl Salicylic Acid 100 mg coated tablets)
was prescribed for the LDA group before pregnancy and
continued till 36 weeks gestation.
Side effects of both treatment groups like gastritis,
vaginal bleeding, echymosis, and abruption placentae were
recorded.
Ethical approval
The study was approved by the scientiﬁc committee in the
Maternity teaching hospital and the patients gave their
written informed consent after full explanation of the aims
of the study and conﬁdentiality was approved.
Statistical analysis
Statistical analysis was conducted using the Statistical
Package for Social Sciences (SPSS version 18). Data were
described using mean, standard deviation for contentious
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pendent t test was used to analyze the difference between 2
meanvalues. Levene’s test was used for equality of vari-
ance. Chi-square test was used to analyze the difference
between proportions. A P\0.05 was considered statisti-
cally signiﬁcant.
Results
Baseline characteristics
A total of 141 women were enrolled in this study, with 61
ladies assigned to receive Low dose Aspirin (LDA) and 80
cases assigned to LMWH (Bemiparin). Table 1 shows the
baseline characteristics of participants according to the
treatment groups (Table 2).
The mean age of the women who received LDA was
30.61 ± 6.325 years and the mean age of women who
received Bemiparin was 31.44 ± 5.811 years. The mean
parity in LDA group was 1.02 ± 1.478 while in the
Bemiparin group the mean parity number was 1.29 ±
1.398. The mean number of preceding abortions was
3.4 ± 1.76 in LDA group versus 3.28 ± 1.72 in Bemiparin
group.
The primary aborters (P0) in the LDA group was 57.4
versus 42.6% of cases who presented with a secondary
abortion (patients with previous successful deliveries),
while in the Bemiparin group 43.8% of cases were primary
aborters and 56.35% of cases presented with secondary
abortion; this difference was statistically not signiﬁcant
between the two treatment groups. Using contingency
coefﬁcient test (P value = 0.16) (Table 2).
Mode of delivery
About two-thirds of women in the LDA and Bemiparin
groups gave birth to live infants through vaginal delivery
(61 and 62%, respectively) (Table 3).
About one-third of cases in both treatment groups
delivered abdominally (38.63% in LDA group vs. 37.1% in
Bemiparin group); the indications for Cesarean sections
were all based on obstetrical indications as revealed in
Table 4.
Using Levine’s test for equality of variance and t test for
equality of means regarding the indications for cesarean
section in both treatment groups, with 95% conﬁdence
interval, the mean difference was 0.63, lower limit 0.515,
upper limit 0.64, and a standard error difference 0.29
(Table 5); there was no difference between the two groups
regarding the indications for cesarean section.
Outcomes
There was a statistically signiﬁcant difference between the
two treatment groups regarding live birth rate. The
Table 1 Shows the baseline characteristics of participants according
to treatment groups
Characters Low dose
aspirin (LDA)
Low molecular
weight heparin
(Bemiparine)
P value
Mean age (year) 30.61 ± 6.325 31.44 ± 5.811 0.425
Age classes
B30 year 32 (52.45%) 34 (42.5%)
[30 year 29 (47.54) 46 (57.5%)
Abortion history 0.650
C3 year 41 (67.21%) 58 (72.5%)
\3 20 (32.78%) 22 (27.5%)
Mean nb. of abortion 3.41 ± 1.76 3.28 ± 1.72
Parity 0.271
B1 35(57.37%) 35(43.75%)
C2 26(42.62) 45(56.25%)
Mean parity nb. 1.02 ± 1.478 1.29 ± 1.398
Table 2 Distribution of cases
according to history of
successful deliveries
P value = 0.109
GRP
ALD Bemiparin Total
Count Total N (%) Count Total N (%) Count Total N (%)
Primary aborters (P0) 35 57.4 35 43.8 70 49.6
Secondary aborters (P C 1) 26 42.6 45 56.3 71 50.4
Total 61 100.0 80 100.0 141 100.0
Table 3 Distribution of cases according to the mode of delivery
Mode of
delivery
Low dose
aspirin group
Low molecular
weight heparin
(Bemiparin)
P value
Vaginal delivery 27 (61.36%) 44 (62.85%) 0.99
Cesarean section 17 (38.63%) 26 (37.14%)
Mean difference 1 ± 0.753 1.20 ± 0.644
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72.13% in the LDA group and 86.25% in the Bemiparin
group, the mean difference between the live birth rate in
both groups was 0.141 (95% Conﬁdence interval of the
difference was, lower limit 0.08 and, upper limit 0.274).
All newborns in the sample size were singleton babies
(Table 6).
In an analysis involving women who gave birth to live
infants, the average birth weight for women was received
LDA was signiﬁcantly lower than those who received
Bemiparin (Table 6).
Normalization of birth weight in both groups using
Levene’s test for equality of variance showed a highly
signiﬁcant difference regarding the gestational age
(P value, 0.000), but there was no signiﬁcant variance
regarding parity (P value, 0.747) as revealed in Table 7.
Failed treatment in both groups resulted in miscarriages
in the ﬁrst trimester before 10 weeks of gestation.
Maternal and fetal complications
All participants in the two treatment groups delivered after
37 weeks of gestation except two cases in the LDA group
and three case in the Bemiparin group who delivered at
32 weeks of gestation (preterm labor), the difference was
statistically not signiﬁcant (P value [0.05). The preterm
infants were admitted to the neonatal intensive care unit in
the Maternity Teaching Hospital and discharged after
1 week in a good condition.
There were no cases of maternal embolic event during
pregnancy or in the postpartum period in both treatment
groups. One woman in the Bemiparin group developed
severe preeclampsia. This woman had type 1 diabetes
mellitus and was on insulin. She was 24 years old with a
history of diabetes for 10 years; her blood sugar was
strictly controlled in all her previous pregnancies, which
ended in miscarriages in the ﬁrst trimester. Blood test for
anticardiolipin antibody was high on more than two occa-
sions, for that reason she was included in our trial being a
case of APS rather than an uncontrolled diabetes causing
RM.
Five cases out of 80 in the Bemiparin group presented
with slight ecchymosis at the injection site.
Table 4 Distribution of cases according to indications for cesarean
section
GRP
LDA Bemiparin
Count Column
Total N
(%)
Count Column
Total N
(%)
Abortion and vaginal
delivery
44 72.1 55 68.8
Indications for cesarean section
Fetal malpresentation 4 6.6 7 8.8
Cephalopelvic
disproportion
1 1.6 5 6.3
Fetal distress in labor 4 6.6 5 6.3
Failure to progress in
labor
3 4.9 3 3.8
Poor obstetric history 2 3.3 3 3.8
Previous C-section 3 4.9 2 2.5
Total 61 100.0 80 100.0
Table 5 Difference between the two groups regarding indications for cesarean section
Indication for cesarean section Levene’s test for equality of
variances
t test for equality of means
F Sig. T df Sig.
(2-tailed)
Mean
difference
Std. error
difference
95% Conﬁdence
interval of the
difference
Lower Upper
Equal variances assumed 0.668 0.415 0.220 139 0.826 0.06332 0.28793 -0.50598 0.63261
Equal variances not assumed 0.217 121.021 0.829 0.06332 0.29243 -0.51562 -0.64226
Table 6 Distribution of cases according to live birth rate and fetal
weight in both groups
Low dose aspirin
group
LMWH
(Bemiparin) group
P value
Live birth rate 44 (72.13%) 69 (86.25%) 0.045
Mean fetal
weight (kg)
2.323 ± 1.50 3.129 ± 1.263 0.001
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In this trial we found that the use of the new second gen-
eration LMWH (Bemiparin) in patients with history of RM
due to APS improves the live birth rate in comparison to
LDA alone. The live birth rate was 86.25% in the LMWH
group versus 72.13% in the LDA alone group.
The present standard of care for women with aPL and
RPL is treatment with heparin and low dose aspirin [17].
There have been a number of randomized control trials for
patients with RPL due to aPL evaluating either unfrac-
tionated heparin (UFH) or LMWH over the past 15 years.
Each trial determined its inclusion criteria; however,
regardless of differences in aPL status among the various
trials, the live birth rates were similar ranging from 71.1 to
84%. The only signiﬁcant differences among trial outcomes
were in the LDA-only treatment arms: the live birth rates in
those varied from a low of 42.2% to a high of 80% [18].
To date, studies conﬁrmed that treatment with LMWH
plus LDA should be considered as the standard therapy for
recurrent pregnancy loss due to aPL [19, 20]. All these
previous studies used previously wellknown LMWH like
Enoxaprin. Also, there were many studies also using hep-
arin alone or in combination with LDA with different
success rates regarding live birth rate. Using a new LMWH
in the current trial, we suspect the results to be similar to
the reults of previous published trials using other LMWHs.
Bemiparin was the ﬁrst LMWH to be marketed in our
city since 2007; formerly UFH was available with unrec-
ognized sources because of the political problems of Iraqi
people.
Our trial is regarded as the ﬁrst to be published on
pregnant ladies receiving Bemiparin from the time of
diagnosis of pregnancy and up to 36 weeks of gestation,
and having a success rate of 86% in cases of APS associ-
ated with RPL.
There were no major adverse events associated with
both treatment arms and this result was in agreement with
an RCT done by Carl et al. to compare live birth rates in
women with RPL and either autoantibodies or a coagula-
tion abnormality, treated with heparin plus aspirin
(LMWH/ASA) or ASA alone [19].
The mean birth weight for newborns was higher in the
Bemiparin group. Because there was no head-to-head study
comparing LMWH (Bemiparin) versus LDA for prevention
of RPLin the ﬁrst trimesterdue toAPS, the relative effect of
Bemiparin versus LDA regarding birth weight is unknown.
Regarding the single case with type 1 diabetes and being
positive to APS, type 1 diabetes is an indicator of immune
dysregulation that develops as a result of an autoimmune
process. It has been reported that patients with type 1 dia-
betes have a high level of aCL antibodies as a marker of
autoimmune dysregulation [21]. Future research may con-
centrate on cases with good diabetes control but still present
with RM to investigate for other types of autoantibodeis that
may be responsible for the recurrent pregnancy losses.
There were some limitations in the current study that
warrant consideration. The study was stratiﬁed by the
presence of acquired autoantibody syndrome (APS); by
checking for only aPL, inherited thrombophilia was not
tested for in the sample size. We consider it appropriate to
test for a boarder spectrum of autoantibodies in patient
presenting with RPL.
The current study included women with a history of two
or more consecutive ﬁrst trimester miscarriages, depending
on the deﬁnition used by the American College of
Obstetrics and Gynecology [2] rather than the deﬁnition of
three or more miscarriages [6], which is used traditionally
to deﬁne RM. This may have theoretically diluted the result
of the trial. Trials on RPL and the use of different treatment
protocols abroad show that the selection of cases according
to the history of previous miscarriages differ from two to
three RPL with no signiﬁcant difference concluded in the
results depending on the previous number of miscarriages
[18, 22]. Also there was no difference in the pregnancy
outcome in women having a history of less than and more
than three pregnancy losses in both treatment arms in the
current trial.
Table 7 Normalization of birth weight in both groups regarding gestational age and parity
Levene’s test for
equality of variances
t test for equality of means
F Sig. T Sig. (2-tailed) Mean
difference
Std. error
difference
95% conﬁdence
interval of the
difference
Lower Upper
Gestational age Equal variances assumed 330.340 0.000 12.172 0.000 24.043 1.975 20.138 27.949
Equal variances not assumed 10.633 0.000 24.043 2.261 19.521 28.566
Parity Equal variances assumed 0.104 0.747 -1.113 0.268 -0.271 0.244 -0.753 0.210
Equal variances not assumed -1.105 0.271 -0.271 0.245 -0.757 0.215
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randomly assigned to each treatment group, but they were
then made aware of the group to which they were assigned
taking into consideration that the ethical concern of sub-
jecting pregnant women to daily placebo injection for
36 weeks gestation is in favor of using an open label
design.
The use of LDA is on the basis that it is a wellknown
antiplatelet drug that has been used in many previous and
update trials alone or in combination with heparin in cases
of RPL due to APS; its use was either as a treatment arm or
as a control group to compare the efﬁcacy of the new
heparin.
Although the live birth rate of the current study was
high, further research is needed using larger sample sizes,
comparing the drug with a true control group and a com-
bination of the drug with LDA.
Conclusion
The use of the new second generation LMWH (Bemiparin)
in comparison to LDA during pregnancy for prevention of
RM in women with APS is a safe, reliable method with a
high live birth rate and no maternal and fetal complications.
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